<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJMC</journal-id><journal-title-group><journal-title>Open Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="epub">2164-3121</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojmc.2024.141001</article-id><article-id pub-id-type="publisher-id">OJMC-132374</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Synthesis and Physico-Chemical Characterizations of Novel Hydrazone Ligands and Their Metal Complexes against Hormone-Dependent and Independent Cancers
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Sommai</surname><given-names>Patitungkho</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kingkaew</surname><given-names>Patitungkho</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Department of Library and Information Science, Buriram Rajabhat University, Buriram, Thailand</addr-line></aff><aff id="aff1"><addr-line>Department of Chemistry, Buriram Rajabhat University, Buriram, Thailand</addr-line></aff><pub-date pub-type="epub"><day>29</day><month>03</month><year>2024</year></pub-date><volume>14</volume><issue>01</issue><fpage>1</fpage><lpage>13</lpage><history><date date-type="received"><day>7,</day>	<month>March</month>	<year>2024</year></date><date date-type="rev-recd"><day>26,</day>	<month>March</month>	<year>2024</year>	</date><date date-type="accepted"><day>29,</day>	<month>March</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial International License (CC BY-NC).http://creativecommons.org/licenses/by-nc/4.0/</license-p></license></permissions><abstract><p>
 
 
  This work deals with the synthesis and physicochemical characterizations of a new group of novel retinoidal ligands and their metal complexes. Their 
  in v
  i
  tro anti-proliferative activities have shown that ligand 
  <b>L1</b> is effective against human breast cancer BT-20 and MCF-7 cell lines. At the same time, compound 
  <b>L2</b> exerts its effect on human prostate cancer PC-3 and human breast cancer MDA-MB-231 and MCF-7 cell lines respectively. The retinoid ligands exert their pleiotropic action toward retinoic acid receptors (RARs) than their metal complexes but all compounds exhibit concentration-dependent.
 
</p></abstract><kwd-group><kwd>Metal Complexes</kwd><kwd> Cancers</kwd><kwd> Antioxidant</kwd><kwd> Hydrazone</kwd><kwd> Retinoid Receptors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Retinoid is a term used to describe both naturally occurring forms of vitamin A and its analogs [<xref ref-type="bibr" rid="scirp.132374-ref1">1</xref>] . Retinoids have been shown to have multiple therapeutic benefits, such as inhibition of inflammation, keratinization [<xref ref-type="bibr" rid="scirp.132374-ref2">2</xref>] , embryonic development, epithelial differentiation, and growth control [<xref ref-type="bibr" rid="scirp.132374-ref3">3</xref>] . Retinoids exert their pleiotropic action toward retinoic acid receptors (RARs) and retinoid x receptors (RXRs) which belong to nuclear receptors superfamily [<xref ref-type="bibr" rid="scirp.132374-ref4">4</xref>] . There are currently two orally administered retinoids in common use: isotretinoid and etretinate [<xref ref-type="bibr" rid="scirp.132374-ref2">2</xref>] . Chemically, the retinoids are defined as diterpenoids derived from a monocyclic parent compound containing five carbon-carbon double bonds and a functional group at the terminus of the acyclic portion. However, this definition does not account for more potent, newer synthetic retinoids such as tri- or tetra-cyclic retinoidal benzoic acid derivatives, which may not be diterpenoids or may not be derived from the monocyclic parent compound. Structures of certain retinoids derived from monocyclic structures such as retinol or retinoic acid, as well as multicyclic structures such as retinoidal benzoic acid, can be modified to yield an almost unlimited number of retinoids [<xref ref-type="bibr" rid="scirp.132374-ref5">5</xref>] . During the past decade, more than a thousand retinoids and retinoid-like compounds with modified molecular structures have been synthesized and tested in a variety of animal and cell culture systems for their therapeutic effects both in dermatological diseases and neoplastic disorders [<xref ref-type="bibr" rid="scirp.132374-ref6">6</xref>] . However, to characterize the biological activity and toxicity of new retinoids an enormous number of in vivo and in vitro experiments have to be performed. Interestingly, almost of retinoids show low toxicity and play a key role in differentiation, proliferation, and apoptosis [<xref ref-type="bibr" rid="scirp.132374-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref9">9</xref>] . The description above prompted us to study by focusing on synthetic compounds with improved more effective retinoids for modulating cell differentiation and proliferation against human estrogen-independent breast cancer cell lines (BT-20 and MDA-MB-231) and human estrogen-dependent breast cancer cell lines (MCF-7).</p></sec><sec id="s2"><title>2. Experimental</title><sec id="s2_1"><title>2.1. Chemical Materials</title><p>All chemical materials employed in the present work were purchased from Aldrich Chemicals (USA). All solvents were used of AR grade and were purified by standard method before use.</p></sec><sec id="s2_2"><title>2.2. Physical Measurements</title><p>Infrared spectra were recorded with Infrared spectra were recorded as KBr disc on a Perkin Elmer 283-B infrared spectrophotometer. The analysis of C, H, and N components of the compounds and their metal complexes was performed on CHNS/O ANALYSER (Perkin Elmer PE2400 Series II). Electronic absorption spectra were recorded on Spectronic Genesys-2 and Perkin-Elmer Lambda 20 UV-VIS spectrophotometer using a matched pair of 1 cm quartz cells. Electrochemical properties were measured in DMSO solvent on BAS CV-27 instrument in conjunction with X-Y recorder using a three-compartment cell consisting of the platinum working electrode, a platinum wire as an auxiliary electrode, and saturated calomel as a reference electrode (SCE) with 0.1 M TEAP as a supporting electrolyte in our laboratory. Magnetic susceptibilities of their metal complexes were measured at 300 K on a Faraday balance having a field strength of 7000 KG by using Hg[Co(SCN)<sub>4</sub>] as a calibrant and ESR studies were carried out in Electron Spin Resonance Model JES-RE2X, Jeol, Japan, Microwave: X-Band, using Mn<sup>2+</sup> Marker as a standardization.</p></sec><sec id="s2_3"><title>2.3. Antioxidant Activity by DPPH Method</title><p>The assay was performed as described by Sharma et al. [<xref ref-type="bibr" rid="scirp.132374-ref10">10</xref>] , and the DPPH radical scavenging activity of the compounds was measured. Briefly, 0.2 mM of 2,2-Diphenyl-1-picrylhydrazyl (DPPH) solution was prepared with a methanolic solvent. 100 mL sample was added to 3.9 cm<sup>3</sup> DPPH solution and was incubated in the dark for 30 min at a temperature of 37˚C then the absorbance was measured at λ<sub>max</sub> 517 nm, calculating the percentage of anti-free radical activities.</p></sec><sec id="s2_4"><title>2.4. Antioxidant Activity by FRAP Method</title><p>Prepare FRAP (ferric reducing/antioxidant power) by preparing acetate buffer pH 3.6, 10 mM TPTZ (2,4,6-tris(2-pyridyl-s-trizine)) in solution 40 mM of HCl, and 20 mM of ferric chloride and then mix at the proportion of 10:1:1 (v/v). This will get FRAP solution, then prepare sample solution in purified water with the required concentrations [<xref ref-type="bibr" rid="scirp.132374-ref10">10</xref>] .</p></sec><sec id="s2_5"><title>2.5. Antiproliferative Activities to Cancer Cell Lines</title><p>The breast (MCF-7, MDA-MB-231, BT-20) and prostate (PC-3) cancer cell lines during growth stage (9 &#215; 10<sup>4</sup> cell/mL) 45 mL. Add sample element 5 mL diluted by DMSO 5% mixed with 384-well plated and incubate at a temperature of 37˚C with 5% of CO<sub>2</sub> for 3 days, then add solution resazurin 62.5 mg/mL 12.5 mL, incubate 4 hours at a temperature of 37˚C. Then draw a graph for the relation between the concentration and the value of the response of cell inhibition [<xref ref-type="bibr" rid="scirp.132374-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref13">13</xref>] .</p></sec><sec id="s2_6"><title>2.6. Statistical Analysis</title><p>All determinations of samples were determined in triplicate and mean values were reported for each case along with standard deviation (&#177;SD). The antioxidant activities of the compounds were by ANOVA one-way test, using SPSS program (p &lt; 0.05).</p></sec></sec><sec id="s3"><title>3. Synthesis</title><sec id="s3_1"><title>3.1. Synthesis of Ligands (L1, L2)</title><p>Ligands were synthesized by interacting of (3R)-(+)-citronellal with hydrazide by mole ratio 1:1 in MeOH at 60˚C for 6 h as in Scheme 1. The corresponding compound was filtrated and dried properly in vacuo. The compounds yielded 80% for L1 and 95% for L2, respectively. [L1 Found C 60.75, H 8.23, N 4.45, O 25.38; C<sub>16</sub>H<sub>29</sub>NO<sub>5</sub> calc C 60.88, H 9.19, N 4.44, O 25.36, i.r. spectra (KBr disc): 3228 cm<sup>−1</sup> n(N-H), 1658 cm<sup>−1</sup> n(C=O), 1550 cm<sup>−1</sup> n(C=N)]. [L2 Found C 70.83, H 8.33, N 9.72, O 5.55; C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O calc C 70.74, H 8.32, N 9.71, O 5.55, i.r. spectra (KBr disc): 3265 cm<sup>−1</sup> n(N-H), 1647 cm<sup>−1</sup> n(C=O), 1537cm<sup>−1</sup> n(C=N)].</p></sec><sec id="s3_2"><title>3.2. Synthesis of Metal Complexes (C1-C4)</title><p>Metal complexes were synthesized using an identical procedure as shown in</p><p>Scheme 1. Copper (II) chloride dihydrate was added to citronellal hydrazone in methanol solvent at a proper stoichiometry in molar ratio 1:1. The product was separated by centrifugation and dried in a vacuum. The reaction was carried out in darkness and without heating for 3 h. The products were gained 67% for C1, 73% for C2, 75% for C3, 70% for C4, respectively. [C1 Found C 44.45, H 7.20, N 3.32, O 20.35, Cu 14.65; Cu(C<sub>16</sub>H<sub>29</sub>NO<sub>5</sub>(H<sub>2</sub>O)Cl) calc C 44.40, H 7.17, N 3.24, O 20.22, Cu 14070; i.r. spectra (KBr disc): 1525 cm<sup>−1</sup>n (C=N), 1616 cm<sup>−1</sup> n(C=N-N=C), 1373 cm<sup>−1</sup> n(C-O)]. [C2 Found C 50.30, H 6.82, N 6.87, O 7.80, Cu 15.70; Cu(C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O(H<sub>2</sub>O)Cl) calc C 50.30, H 6.41, N 6.91, O 7.89, Cu 15.68; i.r. spectra (KBr disc): 1530 cm<sup>−1</sup> n(C=N), 1610 cm<sup>−1</sup> n(C=N-N=C), 1350 cm<sup>−1</sup> n(C-O)]. [C3 Found C 38.25, H 6.20, N 5.63, O 28.59, Ag 21.45; Ag(C<sub>16</sub>H<sub>29</sub>NO<sub>5</sub>- (NO<sub>3</sub>)(H<sub>2</sub>O)) calc C 38.15, H 6.16, N 5.56, O 28.61, Ag 21.43; i.r. spectra (KBr disc): 1635 cm<sup>−1</sup> n(C=N), 1615 cm<sup>−1</sup> n(C=N-N=C), 1370 cm<sup>−1</sup> n(C-O)]. [C4 Found C 42.79, H 5.06, N 8.75, O 16.85, Ag 22.70; Ag(C<sub>17</sub>H<sub>24</sub>N<sub>2</sub>O(NO<sub>3</sub>)(H<sub>2</sub>O)) calc C 42.83, H 5.04, N 8.82, O 16.80, Ag 22.65; i.r. spectra (KBr disc): 1638 cm<sup>−1</sup> n(C=N), 1615 cm<sup>−1</sup> n(C=N-N=C), 1372 cm<sup>−1</sup> n(C-O)].</p></sec></sec><sec id="s4"><title>4. Result and Discussions</title><sec id="s4_1"><title>4.1. Physicochemical Characterization of Samples</title><p>Physicochemical properties of compounds from synthesis, both ligands; Citronellal d-glucosamine hydrazone (L1) Citronellal salicylic hydrazone (L2), and complexes between ligands and metal ions (Cu<sup>2+</sup> and Ag<sup>+</sup>) are C1, C2, C3 and C4 produced from Scheme 1. All synthesized substances are polar compounds but polarity is high in ligands. These ligands are reacted with Lewis acid (copper and silver) to form C1, C2, C3, and C4 complexes with reduced polarity due to reduced charge. This is caused by the neutralization of negatively charged ligands with positively charged metal ions of copper and silver. The synthesized substances will have molecular weight, color, and soluble solvents as shown in <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>Both ligands and complexes synthesized in this research showed high percentage yields by condensation reaction between natural aldehyde and hydrazide in a 1:1 mass stoichiometric ratio. From the study of chemical composition, it was found that complexes have a general formula as [M(ligand)(H<sub>2</sub>O)(NO<sub>3</sub>)/Cl], corresponding to our previous studies [<xref ref-type="bibr" rid="scirp.132374-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref15">15</xref>] and others [<xref ref-type="bibr" rid="scirp.132374-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref17">17</xref>] .</p></sec><sec id="s4_2"><title>4.2. Electronic Spectroscopy</title><p>The electronic spectra of (3R)-(+)-citronellal hydrazones and their metal complexes are recorded in DMSO solvent. The complexes exhibit two bands and showed a blue shift compared with their ligands: one band in the region 10,627 - 13,459 cm<sup>−1</sup>, and another band in the region 29,851 - 30,120 cm<sup>−1</sup> region. The copper (II) complexes of these ligands showed moderate Jahn-Teller distortion the lowest energy transition d z 2 → d x − y 22 ( B 2 1 g → B 2 2 g ) occurred in the 10,627 - 13,459 cm<sup>−1</sup> similar to previously reported of Mandal et al. [<xref ref-type="bibr" rid="scirp.132374-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref19">19</xref>] . However, the high-intensity bands observed at the lower wavelength region (29,851 - 30,120 cm<sup>−1</sup>) are due to p-p* transition of the imino functionality [<xref ref-type="bibr" rid="scirp.132374-ref20">20</xref>] .</p></sec><sec id="s4_3"><title>4.3. Infrared Spectroscopy</title><p>The data show bands corresponding to the imide n(N-H) and the keto n(C=O) groups suggesting that in the solid state, the ligands exist in the keto form [<xref ref-type="bibr" rid="scirp.132374-ref21">21</xref>] . In spectra of complexes, the blue shift of imine n(C=N) spectral bands of citronellal hydrazones from about (1537 - 1550 cm<sup>−1</sup>) to (1525 - 1530 cm<sup>−1</sup>) for the metal complexes indicating the coordination of the azomethine nitrogen and corresponding to n(N=N) from (957 - 977 cm<sup>−1</sup>) to (1024 - 1037 cm<sup>−1</sup>) expected to reduce the electron density in the azomethine group and also the bands expected for n(N-H) and n(C=O) disappeared to produce new bands about (1610 - 1616 cm<sup>−1</sup>) and (1350 - 1373 cm<sup>−1</sup>) can determine for the characteristic of the azomethine [n(C=N-N=C)] and n(C-O) group, respectively. The coordination of azomethine nitrogen is confirmed with the presence of a new band at about 414 - 424 cm<sup>−1</sup> and 532 - 553 cm<sup>−1</sup> assignable to n(Cu-N), n(Cu-O) and 1638 cm<sup>−1</sup>, 1372 cm<sup>−1</sup> assignable to n(Ag-N), n(Ag-O), respectively. The presence of coordinated water molecules in the complexes of broad bands in the region about 3540 - 3350 cm<sup>−1</sup> [<xref ref-type="bibr" rid="scirp.132374-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref24">24</xref>] .</p></sec><sec id="s4_4"><title>4.4. Magnetic Susceptibility and EPR Studied</title><p>The magnetic moment (m<sub>eff</sub>, BM) values of (3R)-(+)-citronellal hydrazone copper and silver complexes have shown in the range 1.70 - 1.75 B.M. as shown in <xref ref-type="table" rid="table2">Table 2</xref>. These values expected for square-planar ligation about the copper (II) ion is probable [<xref ref-type="bibr" rid="scirp.132374-ref25">25</xref>] and indicate them to be monomeric. For which the EPR spectra of compounds were recorded in DMSO solvent at liquid nitrogen</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Physicochemical properties of samples</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Trivial name</th><th align="center" valign="middle" >Code</th><th align="center" valign="middle" >MW</th><th align="center" valign="middle" >Color of samples</th><th align="center" valign="middle" >Solvents</th></tr></thead><tr><td align="center" valign="middle" >Cit-D-Glu</td><td align="center" valign="middle" >L1</td><td align="center" valign="middle" >315.40</td><td align="center" valign="middle" >reddish brown</td><td align="center" valign="middle" >DMSO, DMF, MeOH, EtOH</td></tr><tr><td align="center" valign="middle" >Cit-Sal</td><td align="center" valign="middle" >L2</td><td align="center" valign="middle" >288.38</td><td align="center" valign="middle" >White</td><td align="center" valign="middle" >DMSO, DMF, MeOH, EtOH</td></tr><tr><td align="center" valign="middle" >Cit-D-Glu-Cu</td><td align="center" valign="middle" >C1</td><td align="center" valign="middle" >432.40</td><td align="center" valign="middle" >Green</td><td align="center" valign="middle" >DMSO, DMF, MeOH, EtOH</td></tr><tr><td align="center" valign="middle" >Cit-Sal-Cu</td><td align="center" valign="middle" >C2</td><td align="center" valign="middle" >405.37</td><td align="center" valign="middle" >Green</td><td align="center" valign="middle" >DMSO, DMF, MeOH, EtOH</td></tr><tr><td align="center" valign="middle" >Cit-D-Glu-Ag</td><td align="center" valign="middle" >C3</td><td align="center" valign="middle" >503.27</td><td align="center" valign="middle" >Black</td><td align="center" valign="middle" >DMSO, DMF, MeOH, EtOH</td></tr><tr><td align="center" valign="middle" >Cit-Sal-Ag</td><td align="center" valign="middle" >C4</td><td align="center" valign="middle" >476.25</td><td align="center" valign="middle" >Gray</td><td align="center" valign="middle" >DMSO, DMF, MeOH, EtOH</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Magnetic moment and EPR parameters of (3R)-(+)-citronellal hydrazonate copper complexes (C1-C2) and silver complexes (C3-C4)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Samples</th><th align="center" valign="middle"  rowspan="2"  >m<sub>eff</sub> (BM)</th><th align="center" valign="middle"  rowspan="2"  >g<sub>//</sub></th><th align="center" valign="middle"  rowspan="2"  >g<sub>^</sub></th><th align="center" valign="middle"  colspan="2"  >A<sub>//</sub></th><th align="center" valign="middle"  rowspan="2"  >f (cm)</th></tr></thead><tr><td align="center" valign="middle" >(mT)</td><td align="center" valign="middle" >(&#215;10<sup>−4</sup> cm<sup>−1</sup>)</td></tr><tr><td align="center" valign="middle" >C1</td><td align="center" valign="middle" >1.72</td><td align="center" valign="middle" >2.42</td><td align="center" valign="middle" >2.07</td><td align="center" valign="middle" >15.6</td><td align="center" valign="middle" >176</td><td align="center" valign="middle" >137</td></tr><tr><td align="center" valign="middle" >C2</td><td align="center" valign="middle" >1.70</td><td align="center" valign="middle" >2.30</td><td align="center" valign="middle" >2.05</td><td align="center" valign="middle" >13.8</td><td align="center" valign="middle" >148</td><td align="center" valign="middle" >155</td></tr><tr><td align="center" valign="middle" >C3</td><td align="center" valign="middle" >1.75</td><td align="center" valign="middle" >2.51</td><td align="center" valign="middle" >2.07</td><td align="center" valign="middle" >16.5</td><td align="center" valign="middle" >165</td><td align="center" valign="middle" >145</td></tr><tr><td align="center" valign="middle" >C4</td><td align="center" valign="middle" >1.74</td><td align="center" valign="middle" >2.51</td><td align="center" valign="middle" >2.11</td><td align="center" valign="middle" >16.3</td><td align="center" valign="middle" >172</td><td align="center" valign="middle" >138</td></tr></tbody></table></table-wrap><p>g<sub>//</sub> = g<sub>parallel</sub>, g<sub>^</sub> = g<sub>perpendicular</sub>.</p><p>temperature and these spectra showed a set of four well-resolved peaks at the low-field region and another weaker signal at the high-field region corresponding to g<sub>//</sub> and g<sub>^</sub>, respectively. The observed g<sub>//</sub> values for citronellal hydrazone copper and silver complexes 2.30 and 2.51 suggest the presence of a small amount of ionic character of the metal-ligand bond. The g<sub>//</sub> &gt; g<sub>^</sub> &gt; 2.0023 were observed for these compounds plausible that the unpaired electron is localized in d x − y 22 orbital of the copper (II) ion [<xref ref-type="bibr" rid="scirp.132374-ref26">26</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref27">27</xref>] . The axial symmetry parameter G is defined as G= [g<sub>//</sub> - 2.0023]/[g<sub>^</sub>- 2.0023]. The calculated G values for these compounds indicate that there are no magnetic interactions between the copper and silver centers in DMSO medium.</p></sec><sec id="s4_5"><title>4.5. Cyclic Voltammetry of Complexes (C1-C4)</title><p>The cyclic voltammetric profile of citronellal hydrazonate metal complexes recorded in the range +1.0 and −1.5 V were given and the redox potentials of all compounds are summarized as shown in <xref ref-type="table" rid="table3">Table 3</xref>. All complexes show a redox couple in the +0.18 to +0.26 V ascribed to Cu<sup>2+/1+</sup> redox process. The different DE<sub>p</sub> = E<sub>pc</sub> − E<sub>pa</sub> exceeds the Nernstain requirement of 0.059 V suggesting that all of them showed the reversible character and the anodic to cathodic peak current ratio (i<sub>pa</sub>/i<sub>pc</sub>) is equal to unity even though the scan rate was varied between 100</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Electrochemical data on metal complexes of (3R)-(+)-citronellal hydrazonates at 298 k<sup>a</sup></title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Compound</th><th align="center" valign="middle" >E<sub>pc</sub>(v)</th><th align="center" valign="middle" >E<sub>pa</sub>(v)</th><th align="center" valign="middle" >E<sub>1/2</sub></th><th align="center" valign="middle" >E<sub>pc</sub>/E<sub>pa</sub></th><th align="center" valign="middle" >DE<sub>p</sub></th></tr></thead><tr><td align="center" valign="middle" >C1</td><td align="center" valign="middle" >+0.16 −0.98</td><td align="center" valign="middle" >+0.20</td><td align="center" valign="middle" >+0.18</td><td align="center" valign="middle" >0.90</td><td align="center" valign="middle" >0.07</td></tr><tr><td align="center" valign="middle" >C2</td><td align="center" valign="middle" >+0.21 −0.58</td><td align="center" valign="middle" >+0.30 −0.43</td><td align="center" valign="middle" >+0.26</td><td align="center" valign="middle" >0.92</td><td align="center" valign="middle" >0.09</td></tr><tr><td align="center" valign="middle" >C3</td><td align="center" valign="middle" >−0.09 −0.29</td><td align="center" valign="middle" >−0.15 −0.48</td><td align="center" valign="middle" >+0.70</td><td align="center" valign="middle" >0.60</td><td align="center" valign="middle" >0.06</td></tr><tr><td align="center" valign="middle" >C4</td><td align="center" valign="middle" >−0.10 −0.30</td><td align="center" valign="middle" >−0.17 −0.47</td><td align="center" valign="middle" >+0.69</td><td align="center" valign="middle" >0.58</td><td align="center" valign="middle" >0.07</td></tr></tbody></table></table-wrap><p><sup>a</sup>In DMSO solvent.</p><p>and 300 mVs<sup>−1</sup> which indicate the chemical reversibility of the redox nature change of the metal redox couple for complexes. An irreversible one-electron reduction wave at ca. −0.58 to −0.98 V of these compounds is attributable to the Cu<sup>1+/0</sup> reduction [<xref ref-type="bibr" rid="scirp.132374-ref28">28</xref>] . The facile interconversions of the Cu<sup>2+/1+</sup> valencies observed for the present complexes might be relevant to the biological activities of copper complexes [<xref ref-type="bibr" rid="scirp.132374-ref29">29</xref>] .</p></sec><sec id="s4_6"><title>4.6. Biological Activities</title><p>Antioxidant activity: The ability of anti-free radical activities by using the DPPH and FRAP methods. The calculation of the inhibitory concentration 50% is illustrated in <xref ref-type="table" rid="table4">Table 4</xref>. It is found that the novel Schiff base ligands anti-free radical DPPH at a high percentage. All compounds showed anti-free radical DPPH and also showed a concentration dependence on both ligands and their metal complexes but hydrazonate metal complexes have lower proficiency than independent ligands because of the bigger structure resulting in the steric effect that makes it difficult to provide hydrogen-free radical. For anti-free radical activity by reducing Fe<sup>3+</sup> to Fe<sup>2+</sup> (FRAP). It is found that ligands and their complexes showed low ability to reduce iron because the molecule has difficulty in providing single electron transfer. Antioxidants have a differing capacity to stop the propagation of free radicals, influencing this both the structure of the antioxidant and the structure of the compounds to be oxidized [<xref ref-type="bibr" rid="scirp.132374-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref31">31</xref>] .</p><p>Many chemopreventive agents, viz. retinoids and anti-estrogens are believed to block or delay the progression of transformed cells by modulating cell proliferation or differentiation [<xref ref-type="bibr" rid="scirp.132374-ref32">32</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref33">33</xref>] . Retinoids including classical and non-classical retinoids have been shown to modulate cellular growth and differentiation of normal and neoplastic epithelial cells by interacting with nuclear receptors that function as retinoid-dependent transcription factors [<xref ref-type="bibr" rid="scirp.132374-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref35">35</xref>] [<xref ref-type="bibr" rid="scirp.132374-ref36">36</xref>] . Although classical retinoids viz. all-trans-retinoic acid (ATRA) possess apoptosis induction this effect is weak and is only seen when these compounds are used at supraphysiological concentrations and long-term use shows adverse side effects and resistances [<xref ref-type="bibr" rid="scirp.132374-ref8">8</xref>] . Certain synthetic retinoid-related molecules (non-classical retinoids) were developed with low toxicity and exert high potency for</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Value of IC<sub>50</sub> of sample substances of anti-free radical DPPH and FRAP</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Samples</th><th align="center" valign="middle"  colspan="2"  >IC<sub>50</sub> (Inhibitory concentration 50%)</th></tr></thead><tr><td align="center" valign="middle" >DPPH</td><td align="center" valign="middle" >FRAP</td></tr><tr><td align="center" valign="middle" >L1</td><td align="center" valign="middle" >10.85<sup>c </sup></td><td align="center" valign="middle" >9.77<sup>d </sup></td></tr><tr><td align="center" valign="middle" >L2</td><td align="center" valign="middle" >28.34<sup>a</sup></td><td align="center" valign="middle" >13.70<sup>b </sup></td></tr><tr><td align="center" valign="middle" >C1</td><td align="center" valign="middle" >7.83<sup>d,e </sup></td><td align="center" valign="middle" >12.61<sup>c </sup></td></tr><tr><td align="center" valign="middle" >C2</td><td align="center" valign="middle" >7.11<sup>e </sup></td><td align="center" valign="middle" >7.37<sup>e </sup></td></tr><tr><td align="center" valign="middle" >C3</td><td align="center" valign="middle" >8.03<sup>d </sup></td><td align="center" valign="middle" >14.52<sup>a </sup></td></tr><tr><td align="center" valign="middle" >C4</td><td align="center" valign="middle" >22.43<sup>b </sup></td><td align="center" valign="middle" >12.71<sup>c </sup></td></tr><tr><td align="center" valign="middle" >C.V. (%)</td><td align="center" valign="middle" >0.58</td><td align="center" valign="middle" >0.37</td></tr></tbody></table></table-wrap><p>Note: The different of values: a &gt; b &gt; c &gt; d &gt; e.</p><p>anticancer agents urgently needed. In the present work, six such compounds have been evaluated against human estrogen-dependent breast cancer cell line (MCF-7) and estrogen-independent breast cancer cell lines (BT-20 and MDA-MB-231) as shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig2">Figure 2</xref>, and <xref ref-type="fig" rid="fig3">Figure 3</xref> as well as human androgen-insensitive prostate cancer (PC-3) cell line as shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>, respectively.</p><p>On breast cancer cell lines: Both ligands (L1 and L2) exhibit enhanced inhibitory activity against both ER+ve (MCF-7) and ER-ve (BT-20) cell lines indicating their preferential action on the cancer cells. When analyzed in terms of the sub-type selectivity it becomes apparent that these compounds probably have some preferences for RARα, β sub-type. As a result, they fail to exhibit any inhibition against ER-ve MDA -MB-231 cells having RARγ status. Unfortunately, metal conjugation does not seem to contribute to the enhancement of the activity.</p><p>On prostate cancer cell lines: Almost all compounds show considerably less sensitivity to PC-3 (androgen receptor-independent) cell line except the compound L2 although metal conjugation effects are not necessarily consistent.</p></sec></sec><sec id="s5"><title>5. Conclusion</title><p>Present work thus reveals that citronellal hydrazones are potent inhibitors against ER+ ve as well as ER-ve breast cancer cell lines. Their action is, however, independent of estrogen receptor status. The compounds are also effective against androgen receptor-independent prostate cancer cells giving credence to the importance of retinoid receptors as targets for designing effective antitumor compounds.</p></sec><sec id="s6"><title>Acknowledgments</title><p>The facility support of this work by Rajabhat Buriram University is thankfully acknowledged. We also thank the National Center for Genetic Engineering and Biotechnology (BIOTEC), Scientific and Technological Research Equipment Centre (STREC) Chulalongkorn University, Thailand, Professor Dr. Subhash Padhye, University of Pune, India, and Professor Dr. Fazlul H. Sarkar, Karmanos Cancer Institute, Wayne State Medical School, Detroit, USA.</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s8"><title>Cite this paper</title><p>Patitungkho, S. and Patitungkho, K. (2024) Synthesis and Physico-Chemical Characterizations of Novel Hydrazone Ligands and Their Metal Complexes against Hormone-Dependent and Independent Cancers. Open Journal of Medicinal Chemistry, 14, 1-13. https://doi.org/10.4236/ojmc.2024.141001</p></sec></body><back><ref-list><title>References</title><ref id="scirp.132374-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sun, S.Y. and Lotan, R. (2002) Retinoids and Their Receptors in Cancer Development and Chemoprevention. &lt;i&gt;Critical Reviews in Oncology&lt;/i&gt;/&lt;i&gt;Hematology&lt;/i&gt;, 41, 41-55. &lt;br&gt;https://doi.org/10.1016/s1040-8428(01)00144-5</mixed-citation></ref><ref id="scirp.132374-ref2"><label>2</label><mixed-citation publication-type="book" xlink:type="simple">Kovacs, J.A.J. and Shear, N.H. (1993) Therapeutic Efficacy of Retinoids. In: Koren, G., Ed., &lt;i&gt;Retinoids in Clinical Pratice&lt;/i&gt;:&lt;i&gt; The Risk&lt;/i&gt;-&lt;i&gt;Benefit Ratio&lt;/i&gt;, CRC Press, New York, 1.</mixed-citation></ref><ref id="scirp.132374-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zasada, M. and Budzisz, E. (2019) Retinoids: Active Molecules Influencing Skin Structure Formation in Cosmetic and Dermatological Treatments. &lt;i&gt;Advances in &lt;/i&gt;&lt;i&gt;Dermatology and Allergology&lt;/i&gt;, 36, 392-397. &lt;br&gt;https://doi.org/10.5114/ada.2019.87443</mixed-citation></ref><ref id="scirp.132374-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Fontana, J.A. and Rishi, A.K. (2002) Classical and Novel Retinoids: Their Targets in Cancer Therapy. &lt;i&gt;Leukemia&lt;/i&gt;, 16, 463-472. &lt;br&gt;https://doi.org/10.1038/sj.leu.2402414</mixed-citation></ref><ref id="scirp.132374-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Kuroda, Y., Miyazaki, R., Shimonishi, D., Nakane, D. and Akitsu, T. (2023) Coordination and Photoisomerization of Azobenzene-Amino Acid Schiff Base Copper(II) Complexes to Lysozyme. &lt;i&gt;Journal of Material Science Chemical Engineering&lt;/i&gt;, 11, 34-44. &lt;br&gt;https://doi.org/10.4236/msce.2023.113003</mixed-citation></ref><ref id="scirp.132374-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lisic, E., Grossarth, S., Bowman, S., Hill, J., Beck, M., Deweese, J. and Jiang, X. 2022) New Copper(II), Palladium(II), and Platinum(II) 2-Acetylpyrazine Tert-Bu-tylthiosemicarbazone Complexes: Inhibition of Human Topoisomerase II&lt;i&gt;&amp;#945;&lt;/i&gt; and Activity against Breast Cancer Cells. &lt;i&gt;Open Journal of Medicinal Chemistry&lt;/i&gt;, 12, 1-13. &lt;br&gt;https://doi.org/10.4236/ojmc.2023.121001</mixed-citation></ref><ref id="scirp.132374-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hong, W.K. and Sporn, M.B. (1997) Recent Advances in Chemoprevention of Cancer. &lt;i&gt;Science&lt;/i&gt;, 278, 1073-1077. &lt;br&gt;https://doi.org/10.1126/science.278.5340.1073</mixed-citation></ref><ref id="scirp.132374-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Azieana, J., Zainon, M.N., Noriham, A. and Rohana, M.N. (2017) Total Phenolic and Flavonoid Content and Antioxidant Activities of Ten Malaysian Wild Mushrooms. &lt;i&gt;Open Access Library Journal&lt;/i&gt;, 4, e3987. &lt;br&gt;https://doi.org/10.4236/oalib.1103987</mixed-citation></ref><ref id="scirp.132374-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ommenya, F.K., Nyawade, E.A., andala, D.M. and Kinyua, J. (2020) Synthesis, Characterization and Antibacterial Activity of Schiff Base, 4-Chloro-2-{(E)-[(4-Flu-orophenyl)Imino]Methyl}Phenol Metal (II) Complexes. &lt;i&gt;Journal of Chemistry&lt;/i&gt;, 2020, Article ID: 1745236. &lt;br&gt;https://doi.org/10.1155/2020/1745236</mixed-citation></ref><ref id="scirp.132374-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Prabhu, A., Shanker, K., Muthukrishna, P. and Kathiresan, A. (2016) Electrochemical Studies of Biosynthesized Silver Nanoparticles by Using Setaria Verticillate Plant. &lt;i&gt;Journal of Advanced Chemical Sciences&lt;/i&gt;, 2, 302-304.</mixed-citation></ref><ref id="scirp.132374-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Patole, J., Dutta, S., Padhye, S. and Sinn, E. (2001) Tuning up Superoxide Dismutase Activity of Copper Complex of Salicylaldehyde Semicarbazone by Heterocyclic Bases Pyridine and N-Methy Limidazole. &lt;i&gt;Inorganica Chimica Acta&lt;/i&gt;, 318, 207-211. &lt;br&gt;https://doi.org/10.1016/S0020-1693(01)00416-9</mixed-citation></ref><ref id="scirp.132374-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Minner, E., Lovy, D. and Bill, H. (1993) Electron Paramagnetic Resonance and Relaxation Study of Copper(II) and Silver(II) in CsCdF&lt;sub&gt;3&lt;/sub&gt; Single Crystals. &lt;i&gt;Journal of Chemical Physics&lt;/i&gt;, 99, 6378-6383. &lt;br&gt;https://doi.org/10.1063/1.465876</mixed-citation></ref><ref id="scirp.132374-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Krishna, P.M., Reddy, K.H., Pandey, J.P. and Siddavattam, D. (2008) Synthsis, Characterization, DNA Binding and Nuclease Activity of Binuclear Copper(II) Complexes of Cuminaldehyde Thiosemicarbazones. &lt;i&gt;Transition Metal Chemistry&lt;/i&gt;, 33, 661-668. &lt;br&gt;https://doi.org/10.1007/s11243-008-90947</mixed-citation></ref><ref id="scirp.132374-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">West, D.X., Ives, J.S., Bain, G.A., Liberta, A.E., Vald&amp;#279;s-Martinez, J., Ebert, K.H. and Hernandez-Ortega, S. (1997) Copper(II) and Nickel(II) Complexes of 2,3-Butanedione Bis(N(3)-Substituted Thiosemicarbazone). &lt;i&gt;Polyhedron&lt;/i&gt;, 16, 1895-1905. &lt;br&gt;https://doi.org/10.1016/S0277-5387(96)00468-8</mixed-citation></ref><ref id="scirp.132374-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Hathaway, B.J. and Billing, D.E. (1970) The Electronic Properties and Stereochemistry of Mono-Nuclear Complexes of the Copper(II) Ion.&lt;i&gt; Coordination Chemistry Reviews&lt;/i&gt;, 5, 143-207. &lt;br&gt;https://doi.org/10.1016/s0010-8545(00)80135-6</mixed-citation></ref><ref id="scirp.132374-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lever, A.B.P. (1984) Inorganic Electronic Spectroscopy. 2nd Edition, Elsevier, Amsterdam.</mixed-citation></ref><ref id="scirp.132374-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Nakamoto, K. (2009) Infrared and Raman Spectra of Inorganic and Coordination Compounds Part A: Theory and Applications in Inorganic Chemistry. 6th Edition, John Wiley &amp; Sons, New Jersey. &lt;br&gt;https://doi.org/10.1002/9780470405840</mixed-citation></ref><ref id="scirp.132374-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ramesh, G.N., Prathima, B., Rao, Y.S., Reddy, Y.P., Pai, K.S.R. and Reddy, A.V. (2016) Synthesis, Spectroscopic and Anti-Tumor Studies on Copper(II) Complex of Orthohydroxypropiophenoneisonicoti Noylhydrazone. &lt;i&gt;Arabian Journal of Chem&lt;/i&gt;&lt;i&gt;i&lt;/i&gt;&lt;i&gt;stry&lt;/i&gt;, 9, S404-S410. &lt;br&gt;http://dx.doi.org/10.1016/j.arabjc.2011.05.008</mixed-citation></ref><ref id="scirp.132374-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Rao, C.R.K. and Zacharias, P.S. (1997) Synthesis &amp; Magnetic Properties of Dithiooxamide-Bridged Ni(II) Complexes. &lt;i&gt;Polyhedron&lt;/i&gt;, 16, 1201-1209.&lt;br&gt;https://doi.org/10.1016/S0277-5387(96)00364-6</mixed-citation></ref><ref id="scirp.132374-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Hitchman, M.A. and Waite, T.D. (1976) Electronic Spectrum of Hexaaquocopper(2&lt;sup&gt; &lt;/sup&gt;) Ion. &lt;i&gt;Inorganic Chemistry&lt;/i&gt;, 15, 2150-2154. &lt;br&gt;https://doi.org/10.1021/ic50163a030</mixed-citation></ref><ref id="scirp.132374-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Mandal, S. and Bharadwa, P.K. (1992) Hexa-Coordinated Copper(II) Complexes Having CuN&lt;sub&gt;2&lt;/sub&gt;S&lt;sub&gt;2&lt;/sub&gt;&lt;sup&gt;*&lt;/sup&gt;S&lt;sub&gt;2&lt;/sub&gt; (S&lt;sup&gt;*&lt;/sup&gt;=Thioether) Chromophore: Synthesis, Electrochemistry and Spectroscopy. &lt;i&gt;Polyhedron&lt;/i&gt;, 11, 1037-1042. &lt;br&gt;https://doi.org/10.1016/S0277-5387(00)84471-X</mixed-citation></ref><ref id="scirp.132374-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Dzeikala, A. and Sykula, A. (2018) Schiff Bases as Important Class of Pharmacological Agents. &lt;i&gt;Journal of Pharmacy and Pharmacology&lt;/i&gt;, 6, 989-1009. &lt;br&gt;https://doi.org/10.17265/2328-2150/2018.12.002</mixed-citation></ref><ref id="scirp.132374-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Yusuf, T.L., Oladipo, S.D., Zamisa, S., Kumalo, H.M., Lawal, I.A., Lawal, M.M. and Mabuba, N. (2021) Design of New Schiff-Base Copper(II) Complexes: Synthesis, Crystal Structures, DFT Study, and Biding Potency toward Cytochrome P450 3A4. &lt;i&gt;ACS Omega&lt;/i&gt;, 6, 13704-13718. &lt;br&gt;https://doi.org/10.1021/acsomega.1c00906</mixed-citation></ref><ref id="scirp.132374-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Patitungkho, S., Laeid-On, K. and Patitungkho, K. (2023) Biological Investigation of Nano-Organometallic Agents against Bacteria and &lt;i&gt;Chilo polychrysus&lt;/i&gt;. &lt;i&gt;Journal of &lt;/i&gt;&lt;i&gt;Agricultural Chemistry and Environmental&lt;/i&gt;, 12, 238-249. &lt;br&gt;https://doi.org/10.4236/jacen.2023123018</mixed-citation></ref><ref id="scirp.132374-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ambike, V., Adsule, S., Ahmed, F., Wang, Z., Afrasiabi, Z., Sinn, E., Sarkar, F. and Padhyde, S. (2007) Copper Conjugates of Nimsulide Schiff Bases Targeting VEGF, COX and Bcl-2 in Pancreatic Cancer Cells. &lt;i&gt;Journal of Inorganic Biochemistry&lt;/i&gt;, 101, 1517-1524. &lt;br&gt;https://doi.org/10.1016/j.jinorgbio.2007.06.028</mixed-citation></ref><ref id="scirp.132374-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Patitungkho, S. and Patitungkho, K. (2023) Physicochemical Properties and Biological Activities of Novel Hydrazonate Copper Complexes. &lt;i&gt;Open Journal of Medicinal Chemistry&lt;/i&gt;, 13, 1-13. &lt;br&gt;https://doi.org/10.4236/ojmc.2023.131001</mixed-citation></ref><ref id="scirp.132374-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Patitungkho, S., Adsule, S., Dandawate, P., Padhyde, S., Ahmad, A. and Sarkar, F.H. (2011) Synthesis, Characterization and Anti-Tumor Activity of Moxifloxacin-Copper Complexes against Breast Cancer Cell Lines. &lt;i&gt;Bioorganic Medicinal Chemistry Le&lt;/i&gt;&lt;i&gt;t&lt;/i&gt;&lt;i&gt;ters&lt;/i&gt;, 21, 1802-1806. &lt;br&gt;https://doi.org/10.1016/j.bmcl.2011.01.061</mixed-citation></ref><ref id="scirp.132374-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Vyas, A., Patitungkho, S., Jamadar, A., Adsule, S., Padhye, S., Ahmad, A. and Sakar, F.H. (2012) ATRA-Hydrazonate Derivatives and Their Copper Complexes against Hormone-Dependent (MCF-7), Hormone-Independent (MDA-MB-231 and BT-20) Breast Cancer and Androgen-Independent (PC3) Prostate Cancer Cell Lines. &lt;i&gt;Ino&lt;/i&gt;&lt;i&gt;r&lt;/i&gt;&lt;i&gt;ganic Chemistry Communication&lt;/i&gt;, 23, 17-20. &lt;br&gt;https://doi.org/10.1016/j.inoche.2012.05.027</mixed-citation></ref><ref id="scirp.132374-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Sharma, N.K., Dey, S. and Prasad, R. (2007)&lt;i&gt; In vitro&lt;/i&gt; Antioxidant Potential Evaluation of &lt;i&gt;Euphorbia hirta&lt;/i&gt; L. &lt;i&gt;Pharmacologyonline&lt;/i&gt;, 1, 91-98.</mixed-citation></ref><ref id="scirp.132374-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Altucci, L. and Gronemeyer, H. (2001) The Promise of Retinoids to Fight against Cancer. &lt;i&gt;Nature Reviews&lt;/i&gt;, 1, 181-193. &lt;br&gt;https://doi.org/10.1038/35106036</mixed-citation></ref><ref id="scirp.132374-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Vernia, F., Longo, S., Stefanelli, G., Viscido, A. and Latella, G. (2021) Dietary Factors Modulating Colorectal Carcinogenesis. &lt;i&gt;Nutrients&lt;/i&gt;, 13, Article 143. &lt;br&gt;https://doi.org/10.3390/nu13010143</mixed-citation></ref><ref id="scirp.132374-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Uray, I.P., Dmitrovsky, E. and Brown, P.H. (2016) Retinoids and Rexinoids in Cancer Prevention: From Laboratory to Clinic. &lt;i&gt;Seminars Oncology&lt;/i&gt;, 43, 49-64. &lt;br&gt;https://doi.org/10.1053/j.seminoncol.2015.09.002</mixed-citation></ref><ref id="scirp.132374-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Hunsu, V.O., Facey, C.O.B., Fields, J.Z. and Boman, B.M. (2021) Retinoids as Chemo-Preventive and Molecular-Targeted Anti-Cancer Therapies. &lt;i&gt;Inter&lt;/i&gt;&lt;i&gt;national Jou&lt;/i&gt;&lt;i&gt;r&lt;/i&gt;&lt;i&gt;nal of Molecular Sciences&lt;/i&gt;, 22, Article 7731. &lt;br&gt;https://doi.org/10.3390/ijms22147731</mixed-citation></ref><ref id="scirp.132374-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Jin, Y., Teh, S.S., Lau, H.L.N., Xiao, J. and Mah, S.H. (2022) Retinoids as Anti-Cancer Agents and Their Mechanisms of Action. &lt;i&gt;American of Cancer Research&lt;/i&gt;, 12, 938-960.</mixed-citation></ref><ref id="scirp.132374-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Niles, R.M. (2004) Signaling Pathways in Retinoid Chemoprevention and Treatment of Cancer. &lt;i&gt;Mutation Research&lt;/i&gt;, 555, 81-96. &lt;br&gt;https://doi.org/10.1016/j.mrfmmm.2004.05.020</mixed-citation></ref><ref id="scirp.132374-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Tullio, V., Gasperi, V., Catani, M.V. and Savini, I. (2021) The Impact of Whole Grain Intake on Gastrointestinal Tumors: A Focus on Colorectal, Gastric, and Esophageal Cancers. &lt;i&gt;Nutrients&lt;/i&gt;, 13, Article 81. &lt;br&gt;https://doi.org/10.3390/nu13010081</mixed-citation></ref></ref-list></back></article>